2018年美国《国家综合癌症网络乳腺癌临床实践指南》解读
Interpretation of NCCN clinical practice guideline for breast cancer in 2018
查看参考文献21篇
|
文摘
|
美国国家综合癌症网络( NCCN)于2018年3月20日发布了2018年第1版《NCCN乳腺癌临床实践指南》.该指南结合乳腺癌领域最新的研究进展、新的循证医学证据和理念,在前期版本的基础上制定出当前乳腺癌诊治的指南与规范,供临床医师参考.笔者对最新版本中重要的变更内容进行解读,并结合中国的临床实际探讨其在中国推行的实用性和可行性,主要包括美国癌症联合会第8版乳腺癌TNM分期、保留乳房手术治疗和评估原则、前哨淋巴结活组织检查新进展和系统性治疗新策略4个方面. |
|
其他语种文摘
|
The National Comprehensive Cancer Network ( NCCN) launched the NCCN Clinical Practice Guideline for Breast Cancer ( version 1) on March 20,2018. This guideline reviews the latest research progress and treatment concepts in the field of breast cancer. On the basis of the previous versions,they update the guidelines for the diagnosis and treatment of breast cancer,which can assist physicians in their clinical practices. This paper interpreted the important changes in the latest version,and discussed its practicability and feasibility in China based on clinical practice,including the TNM staging of breast cancer by American Joint Committee on Cancer ( AJCC) ( the eighth edition ) , the principles of breast conserving surgery and pathological evaluation,the recent progress of sentinel lymph node biopsy and new strategy for systematic treatment. |
|
来源
|
中华乳腺病杂志（电子版）
,2018,12(3):129-134 【扩展库】
|
|
DOI
|
10.3877/cma.j.issn.1674-0807.2018.03.001
|
|
关键词
|
乳腺肿瘤
;
诊断
;
治疗学
;
指南
|
|
地址
|
复旦大学附属肿瘤医院乳腺外科, 上海, 200032
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1674-0807 |
|
学科
|
肿瘤学 |
|
文献收藏号
|
CSCD:6283013
|
参考文献 共
21
共2页
|
|
1.
National Comprehensive Cancer Network (NCCN).
NCCN Clinical practice guidelines in oncology: breast cancer. version 1,2018
|
CSCD被引
1
次
|
|
|
|
|
2.
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版).
中国癌症杂志,2017,27(9):695-759
|
CSCD被引
145
次
|
|
|
|
|
3.
Moran M S. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.
J Clin Oncol,2014,32(14):1507-1515
|
CSCD被引
20
次
|
|
|
|
|
4.
Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ.
Ann Surg Oncol,2016,23(12):3801-3810
|
CSCD被引
10
次
|
|
|
|
|
5.
Galimberti V. International Breast Cancer Study Group trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
Lancet Oncol,2013,14(4):297-305
|
CSCD被引
62
次
|
|
|
|
|
6.
Giuliano A E. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial.
JAMA,2017,318(10):918-926
|
CSCD被引
85
次
|
|
|
|
|
7.
Donker M. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised,multicentre,openlabel, phase 3 non-inferiority trial.
Lancet Oncol,2014,15(12):1303-1310
|
CSCD被引
72
次
|
|
|
|
|
8.
Fisher B. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18.
J Clin Oncol,1997,15(7):2483-2493
|
CSCD被引
57
次
|
|
|
|
|
9.
Bear H D. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
J Clin Oncol,2003,21(22):4165-4174
|
CSCD被引
33
次
|
|
|
|
|
10.
Kuehn T. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective,multicentre cohort study.
Lancet Oncol,2013,14(7):609-618
|
CSCD被引
56
次
|
|
|
|
|
11.
Boileau J F. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study.
J Clin Oncol,2015,33(3):258-264
|
CSCD被引
35
次
|
|
|
|
|
12.
Boughey J C. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).
Ann Surg,2015,261(3):547-552
|
CSCD被引
14
次
|
|
|
|
|
13.
Perez E A. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
J Clin Oncol,2011,29(25):3366-3373
|
CSCD被引
26
次
|
|
|
|
|
14.
Slamon D. Adjuvant trastuzumab in HER2-positive breast cancer.
N Engl J Med,2011,365(14):1273-1283
|
CSCD被引
67
次
|
|
|
|
|
15.
von Minckwitz G. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.
N Engl J Med,2017,377(2):122-131
|
CSCD被引
53
次
|
|
|
|
|
16.
Martin M. Neratinib after trastuzumabbased adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised,double-blind,placebo-controlled,phase 3 trial.
Lancet Oncol,2017,18(12):1688-1700
|
CSCD被引
34
次
|
|
|
|
|
17.
Tolaney S M. Adjuvant paclitaxel and trastuzumab for node-negative,HER2-positive breast cancer.
N Engl J Med,2015,372(2):134-141
|
CSCD被引
22
次
|
|
|
|
|
18.
Finn R S. Palbociclib and letrozole in advanced breast cancer.
N Engl J Med,2016,375(20):1925-1936
|
CSCD被引
68
次
|
|
|
|
|
19.
Hortobagyi G N. Ribociclib as first-line therapy for HR-positive,advanced breast cancer.
N Engl J Med,2016,375(18):1738-1748
|
CSCD被引
41
次
|
|
|
|
|
20.
Goetz M P. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer.
J Clin Oncol,2017,35(32):3638-3646
|
CSCD被引
40
次
|
|
|
|
|
了解气象卫星更多信息，请访问